research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
Search
for
Sort by
Research
630-660 / 1000+ results research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Effect of Clitocybin A on the Proliferation of Dermal Papilla Cells
Clitocybin A from a mushroom may promote hair growth by increasing cell activity in hair follicles.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Dual inhibitors of urease and carbonic anhydrase-II from Iris species
Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
research Pharmacological Activity of Cepharanthine
Cepharanthine has many medicinal uses but needs improvement for better effectiveness.
research Is neuronal inhibition or excitability controlled by Na+K+2CL– transporters?
NKCC1 transporters help control neuron excitability and inhibition.
research Hyperactivity and alopecia associated with ingestion of valproic acid in a cat
A cat's hyperactivity and hair loss were caused by eating valproic acid but improved after stopping access to the drug.
research Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research The antimycotic agent clotrimazole inhibits melanogenesis by accelerating ERK and PI3K-/Akt-mediated tyrosinase degradation
Clotrimazole, an antifungal cream, may safely reduce skin pigmentation by breaking down the enzyme needed for making melanin.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
![The Synthesis of (−)-4-Methyl-8-Chloro-Trans-1,2,3,4,4a,5,6,10b-Octahydrobenzo-[f]-Quinolin-3-One-[3-14C] (LY300502-14C) via a Circuitous Route](/images/research/73bab8dc-bdf0-45e3-8ef7-73d0d4b93cb1/small/21074.jpg)
research The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
research 6ER-014 Evaluation of baricitinib in paediatric patients with alopecia areata
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research [Valproic acid, curly hair and weight gain].
Valproic acid can cause weight gain and hair texture changes.
research Lacticaseibacillus Paracasei CCFM1350 Demonstrates Potentials in Hair Growth and Treating Alopecia in Mice
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research Multifunctional antibacterial bioactive nanoglass hydrogel for normal and MRSA infected wound repair
The hydrogel speeds up healing of normal and MRSA-infected wounds.
research Potassium channel openers: pharmacological and clinical aspects
Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
The combination therapy is effective and well-tolerated for treating esophageal cancer.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Generic competition and pharma patent strategies - a sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
research Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
Cal/BD aerosol foam effectively treats scalp psoriasis, improving symptoms and patient satisfaction.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics
The developed nasal gel improves cilostazol delivery to the brain, enhancing its effectiveness and reducing side effects.
research Evaluation of Biological Activity Exerted by an Aza-bicyclocarboxylic acid Derivative using Anischemia-Reperfusion Injury Model
Compound 3 protects the heart from damage by activating A1-adenosine receptors.